People are becoming familiar with Utah's Silicon Slopes, a cluster of information technology and software-development firms.» Read More
June 16- Edwards Lifesciences Corp said on Monday that U.S. health regulators approved its next generation heart valve replacement system for high risk patients and those deemed too frail to endure open heart surgery.
June 16- Medtronic Inc's $43 billion deal for Dublin- based Covidien Plc should accelerate already intense efforts by medical device rivals to seek merger partners, industry analysts and bankers said on Monday.
June 12- Medtronic Inc said on Thursday its minimally invasive heart valve replacement system received U.S. approval to treat patients deemed at high risk for surgery, expanding the eligible patient population for its CoreValve device.
May 20- Medtronic Inc agreed to pay more than $1 billion to rival Edwards Lifesciences Corp to settle patent litigation and keep its CoreValve artificial heart valve on the U.S. market. Edwards was first to market with its Sapien technology in 2011 in the United States, while Medtronic received U.S. regulatory approval for CoreValve in January.
Some of Tuesday's midday movers:
May 20- Medtronic Inc agreed to pay royalties to rival Edwards Lifesciences Corp so it can continue to sell its CoreValve replacement heart valves, the medical device maker said on Tuesday. Medtronic said it would give Edwards a one-time payment of $750 million, plus ongoing royalty payments through April 2022, based on a percentage of CoreValve sales.
May 20- Medtronic Inc said on Tuesday it agreed to pay royalties to rival medical device maker Edwards Lifesciences Corp in a settlement that allows Medtronic to continue to sell its CoreValve replacement heart valves.
LONG BEACH, Calif., April 23- You've been on offense with your global stock portfolio for five years, running up the score in sectors like consumer discretionary and technology stocks that have outperformed the broad market. Jamie Doyle, co-manager of the Causeway Global Value Fund, is not ready to make a wholesale switch into defensive plays.
April 21- A U.S. appeals court on Monday postponed an injunction that would have stopped Medtronic Inc from selling its CoreValve heart valve implant in competition with Edwards Lifesciences Corp's Sapien valve product.
*Citigroup is one of S&P's biggest gainers after results. NEW YORK, April 14- U.S. stocks closed higher on Monday as Citigroup's earnings and strong retail sales gave investors reasons to buy equities despite a resurgence of geopolitical uncertainties.
*Citigroup one of S&P's biggest gainers after results. NEW YORK, April 14- U.S. stocks rose on Monday, rebounding after a sharp selloff in the previous session as strong results from Citigroup and bullish retail sales data lifted sentiment.
Some of Monday midday movers:
April 14- Shares of medical device maker Medtronic Inc fell as much as 6 percent after a U.S. court temporarily halted sales of its aortic heart valve replacement system in the country.
NEW YORK, April 14- U.S. stocks bounced back on Monday, following a sharp selloff last session, with earnings results from Citigroup and retail sales data lifting sentiment while traders kept tabs on the possible escalation of hostilities in Ukraine.
These are the companies making headlines before the bell.
NEW YORK, April 14- U.S. stocks were set to open higher on Monday, following a sharp selloff last session, with earnings results from Citigroup and retail sales data lifting sentiment while traders kept tabs on the possible escalation of hostilities in Ukraine.
*Edwards Lifesciences shares rally after court ruling. *Ukraine's acting president threatens military action. NEW YORK, April 14- U.S. stock index futures edged higher on Monday, following a slarge selloff last session, with earnings results from Citigroup lifting sentiment while traders kept tabs on the possible escalation of hostilities in Ukraine.
Shagun Chadha shares her top pick among medical appliance companies and gives other sector names she likes as well.
A new study boosts fixing a bad aortic valve, the heart's main gate, without open-heart surgery.
WASHINGTON, March 30- The minimally invasive aortic heart valve replacement system from Edwards Lifesciences Corp performed better than a rival product sold by Medtronic Inc in the first head-to-head study of the two, according to data from a small German trial presented at a major heart meeting on Sunday.